Pathway activation strength is a novel independent prognostic biomarker for cetuximab sensitivity in colorectal cancer patients

Cetuximab, a monoclonal antibody against epidermal growth factor receptor (EGFR), was shown to be active in colorectal cancer. Although some patients who harbor K-ras wild-type tumors benefit from cetuximab treatment, 40 to 60% of patients with wild-type K-ras tumors do not respond to cetuximab. Cur...

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Hum Genome Var
Main Authors: Zhu, Qingsong, Izumchenko, Evgeny, Aliper, Alexander M, Makarev, Evgeny, Paz, Keren, Buzdin, Anton A, Zhavoronkov, Alex A, Sidransky, David
Format: Artigo
Sprog:Inglês
Udgivet: Nature Publishing Group 2015
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC4785572/
https://ncbi.nlm.nih.gov/pubmed/27081524
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1038/hgv.2015.9
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker